Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced that CEO David Marek and CFO Uneek Mehra will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 11:00 a.m. Eastern Time. This event aims to provide insights into Myovant's mission to redefine care for both women and men through innovative science and advocacy. The chat will be available for the public to listen via the Myovant website.

Myovant has received FDA and EC approvals for treatments related to prostate cancer and uterine fibroids and is advancing several clinical trials.

BASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.

Investors and the general public are invited to listen to the Goldman Sachs fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

ABOUT MYOVANT SCIENCES
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to two regulatory approvals by the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively. Myovant also has received regulatory approvals by the European Commission (EC) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. Myovant has supplemental New Drug Applications under review with the FDA for endometriosis-associated pain, and for updates to the United States Prescribing Information (USPI) based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years.  Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant also is developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

When will Myovant participate in the Goldman Sachs Healthcare Conference?

Myovant will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 11:00 a.m. Eastern Time.

Who will represent Myovant at the Goldman Sachs conference?

David Marek, CEO, and Uneek Mehra, CFO, will represent Myovant Sciences at the conference.

How can I listen to Myovant's fireside chat?

The fireside chat will be accessible to the public on the Events page of Myovant's website.

What is Myovant Sciences known for?

Myovant Sciences is known for redefining care through innovative treatments for women's and men's health, with regulatory approvals for prostate cancer and uterine fibroids.

What updates has Myovant received from the FDA?

Myovant has received FDA approvals for treatments related to advanced prostate cancer and heavy menstrual bleeding associated with uterine fibroids.